Avalo Therapeutics, Inc.

AVTX

Avalo Therapeutics, Inc.

AVTX

Insider Sentiment (TTM):

Last Purchase:2024-11-13Last Sale:2026-06-23Shares Purchased (TTM):0Shares Sold (TTM):313,465

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:28,701,406Shares Outstanding:20,106,925Institutional Ownership Pct.:142.74%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Series D Preferred Stock	-	0	0	0	0	0	0	0	0	0	0	-
Series E Preferred Stock	-	0	0	0	0	0	0	0	0	0	0	-
Stockholders Equity Note Stock Split Conversion Ra…	-	-	-	-	-	-	-	-	-	-	0	-
Series C Preferred Stock	-	0	0	0	-0	0	0	0	-0	0	0	-
Assets
Inventory Net	-	-	-	-	-	-	-	-	-	-	0	0
Cash And Cash Equivalents At Carrying Value	85	25	16	27	42	125	135	82	93	110	7	10
Assets Current
Assets Current	408	89	105	114	115	127	139	86	96	111	8	13
Short Term Investments	315	57	82	85	71	-	0	-	-	-	-	-
Other Receivables Net Current	-	-	-	-	-	-	1	1	0	0	0	2
Prepaid Expense And Other Assets Current	8	7	7	2	2	2	4	3	2	1	1	1
Restricted Cash And Cash Equivalents At Carrying V…	0	0	0	0	0	0	0	0	0	0	0	0
Goodwill	11	11	11	11	11	11	11	11	11	11	11	14
Restricted Cash And Cash Equivalents Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	491	100	116	125	127	139	151	98	108	124	21	29
Liabilities And Stockhold…
Contract With Customer Liability Current	-	-	-	-	-	-	-	-	-	-	0	0
Accounts Payable Current	3	0	0	0	2	1	0	2	1	1	0	1
Notes Payable Current	-	-	-	-	-	-	-	-	-	-	0	0
Accrued Liabilities And Other Liabilities	18	11	13	7	7	5	6	7	8	7	4	5
Liabilities Current
Liabilities Current	21	12	13	8	9	6	7	61	96	216	5	6
Asset Acquisition Contingent Consideration Liabili…	-	-	-	-	-	-	-	5	5	13	-	-
Derivative Liabilities Current	-	-	0	0	0	0	0	-	-	-	0	-
Long Term Notes Payable	-	-	-	-	-	-	-	-	-	-	0	0
Accrued Royalties Current And Noncurrent	2	2	2	2	2	2	2	2	2	2	2	2
Deferred Income Tax Liabilities Net	0	0	0	0	0	0	0	0	0	0	0	0
Derivative Liabilities Noncurrent	19	18	18	23	10	8	8	12	11	6	6	5
Other Liabilities Noncurrent	0	0	0	0	0	0	0	1	1	1	1	1
Liabilities	42	32	33	34	22	16	18	76	110	225	14	15
Temporary Equity
Temporary Equity Par Or Stated Value Per Share	-	-	-	0.001	0.001	0.001	-	0.001	0.001	0.001	-	-
Temporary Equity Shares Authorized	-	-	-	5	5	5	5	5	5	5	-	-
Temporary Equity Carrying Amount Attributable To P…	0	0	0	0	0	0	0	2	11	11	0	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Stockholders Equity	449	68	83	92	105	123	133	21	-14	-113	7	15
Additional Paid In Capital	954	536	531	526	509	506	503	356	344	344	342	341
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	0	0	-0	-	0	-	-	-	-	-
Retained Earnings Accumulated Deficit	-505	-468	-449	-435	-404	-383	-370	-335	-358	-456	-335	-327
Liabilities And Stockholders Equity	491	100	116	125	127	139	151	98	108	124	21	29
Temporary Equity Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	-
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	53	25	19	18	11	11	10	10	1	1	1	192
Shares Outstanding	53	25	19	18	11	11	10	10	1	1	1	192
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	-	-	-	0.001	-	-	-	-	-
Preferred Stock Shares Authorized	5	5	5	-	-	-	5	-	-	-	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-34.01%	-5.09%	-8.06%	-	-	-	-	-	-	-	-	-
2025	2.50%	24.00%	97.25%	11.26%	29.34%	110.42%	23.22%	19.13%	2.14%	6.89%	31.41%	9.33%
2024	-5.64%	16.36%	-0.18%	-23.64%	-1.33%	30.96%	-26.03%	-35.48%	-41.60%	-40.39%	-50.61%	-50.12%
2023	-	-	-	-	-	-	-33.67%	-61.31%	-81.08%	-	-	-
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	19.31	7.66	8.14	14.28	12.44	22.61	19.96	1.42	0.99	0.52	1.82	2.11
Quick Ratio	18.95	7.08	7.60	14.01	12.23	22.28	19.33	1.37	0.97	0.51	1.64	1.95
Working Capital	386.80M	77.23M	92.35M	105.87M	105.93M	121.33M	131.93M	25.47M	-503.00K	-104.49M	3.78M	6.65M
Leverage & Debt
Debt to Equity	0.09	0.46	0.40	0.37	0.21	0.13	0.13	3.59	-8.12	-2.00	1.87	0.99
Interest Coverage TTM	-16.11	-19.76	-16.76	-14.55	-13.62	-11.56	-20.69	-28.78	-19.38	-18.80	-7.64	-6.42
Debt Ratio	0.09	0.32	0.29	0.27	0.17	0.11	0.12	0.77	1.02	1.82	0.65	0.50
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.02	0.07	0.07
Per Share Metrics
Diluted EPS TTM	-2.30	-4.21	-5.84	-7.13	-4.27	6.94	-4.69	-0.74	-4.73	-166.26	-113.58	-170.33
Free Cash Flow Per Share TTM	-1.57	-2.97	-3.84	-3.73	-4.38	-4.97	-11.08	-6.63	-31.03	-31.22	-111.04	-164.29
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	33.26%	5.56%
Operating Profit Margin TTM	-154,844.07%	-134,164.41%	-123,601.69%	-34,631.25%	-13,640.59%	-11,431.75%	-15,535.60%	-7,675.46%	-6,668.86%	-3,542.17%	-1,421.57%	-1,268.71%
Net Profit Margin TTM	-170,055.93%	-143,627.12%	-132,642.37%	-52,019.79%	-10,479.82%	16,556.01%	-7,965.76%	-971.67%	-4,494.17%	-9,860.52%	-1,639.50%	-1,475.02%
Growth Metrics
Net Revenue Growth (1Y)	-86.62%	-86.62%	-86.62%	-76.56%	-45.29%	-69.57%	-77.08%	-63.60%	-95.25%	-91.65%	-89.34%	-87.05%
Net Income Growth (1Y)	117.10%	-216.06%	122.78%	1,155.06%	27.59%	-151.10%	11.37%	-76.02%	46.25%	383.32%	-24.28%	-34.98%
EPS Growth (1Y)	-46.08%	-160.70%	-26.44%	397.19%	-87.82%	-104.18%	-93.01%	-99.16%	-91.77%	-72.53%	-89.31%	3,041.23%
Valuation Metrics
P/E TTM	-8.03	-3.54	-3.11	-1.78	-1.17	1.15	-0.94	-6.62	-0.36	-0.13	-0.08	-0.17
P/B TTM	1.80	4.39	2.93	1.94	0.52	0.69	0.25	2.50	-0.95	-0.17	0.35	0.39
P/S TTM	13,657.05	5,088.07	4,125.96	926.80	122.54	190.98	74.57	64.33	16.00	12.90	1.31	2.51
Market Cap	805.77M	300.20M	243.43M	177.95M	54.04M	84.22M	32.89M	52.69M	12.90M	18.69M	2.53M	5.66M
Enterprise Value	720.15M	274.88M	227.33M	150.68M	11.52M	-41.01M	-101.81M	-29.34M	-80.66M	-91.62M	-5.02M	-4.65M
Calculated Values
Free Cash Flow TTM	-68.29M	-59.69M	-51.46M	-52.26M	-47.42M	-52.31M	-49.06M	-36.78M	-32.09M	-26.83M	-30.84M	-32.01M
Net Debt	-85.61M	-25.32M	-16.11M	-27.26M	-42.52M	-125.24M	-134.70M	-82.03M	-93.56M	-110.31M	-7.55M	-10.31M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-23Sale

Owner: Doyle, Mittie

Title: Chief Medical Officer

Shares: 1,450

Price/Share: $18.00

Value: $26,100.00

Shares Owned: 51,776

Relationship: Officer

Ownership: Direct

2026-05-28Sale

Owner: Doyle, Mittie

Title: Chief Medical Officer

Shares: 679

Price/Share: $16.00

Value: $10,864.00

Shares Owned: 47,122

Relationship: Officer

Ownership: Direct

2026-05-15Sale

Owner: Doyle, Mittie

Title: Chief Medical Officer

Shares: 3,000

Price/Share: $18.76

Value: $56,280.00

Shares Owned: 3,622

Relationship: Officer

Ownership: Direct

2026-05-07Sale

Owner: Sullivan, Christopher Rya…

Title: Chief Financial Officer

Shares: 18,606

Price/Share: $24.12

Value: $448,776.72

Shares Owned: 423

Relationship: Officer

Ownership: Direct

2026-05-06Sale

Owner: Sullivan, Christopher Rya…

Title: Chief Financial Officer

Shares: 47,000

Price/Share: $20.51

Value: $963,970.00

Shares Owned: 423

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-23	Doyle, Mittie	Officer	Chief Medical Officer	Direct	Sale	1,450	18.00	$26,100.00	51,776	4
2026-05-28	Doyle, Mittie	Officer	Chief Medical Officer	Direct	Sale	679	16.00	$10,864.00	47,122	4
2026-05-15	Doyle, Mittie	Officer	Chief Medical Officer	Direct	Sale	3,000	18.76	$56,280.00	3,622	4
2026-05-07	Sullivan, Christopher Rya…	Officer	Chief Financial Officer	Direct	Sale	18,606	24.12	$448,776.72	423	4
2026-05-06	Sullivan, Christopher Rya…	Officer	Chief Financial Officer	Direct	Sale	47,000	20.51	$963,970.00	423	4
2026-05-06	Doyle, Mittie	Officer	Chief Medical Officer	Direct	Sale	106,555	20.83	$2,219,540.65	3,622	4
2026-05-06	Chan, Mitchell	Director	-	Direct	Sale	3,167	22.88	$72,460.96	3,166	4
2026-05-06	Varki, Paul	Officer	Chief Legal Officer	Direct	Sale	75,063	21.26	$1,595,839.38	3,634	4
2026-04-30	Sullivan, Christopher Rya…	Officer	Chief Financial Officer	Direct	Sale	8,457	13.23	$111,886.11	423	4
2026-04-06	Doyle, Mittie	Officer	Chief Medical Officer	Direct	Sale	3,970	18.01	$71,499.70	3,622	4
2026-04-02	Sullivan, Christopher Rya…	Officer	Chief Financial Officer	Direct	Sale	7,980	17.30	$138,054.00	17,338	4
2026-04-01	Doyle, Mittie	Officer	Chief Medical Officer	Direct	Sale	679	16.00	$10,864.00	3,622	4
2026-03-16	Doyle, Mittie	Officer	Chief Medical Officer	Direct	Sale	25,492	16.15	$411,695.80	3,622	4
2025-11-14	Goldman, Jonathan	Director	-	Direct	Sale	11,367	14.32	$162,775.44	0	4
2024-11-13	Almenoff, June Sherie	Director	-	Indirect	Purchase	500	13.00	$6,500.00	1,000	4
2023-06-27	Armistice, Capital Master…	TenPercentOwner	-	Indirect	Sale	937,404	0.52	$487,450.08	731,458	4
2023-06-26	Caissa, Capital Managemen…	TenPercentOwner	-	Direct	Purchase	182,300	0.62	$113,026.00	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

142.74%

Inst. Shares: 28,701,406

Shares Outstanding: 20,106,925

2025-12-31

148.33%

Inst. Shares: 19,884,047

Shares Outstanding: 13,404,830

2025-09-30

109.40%

Inst. Shares: 15,316,938

Shares Outstanding: 14,000,451

2025-06-30

72.42%

Inst. Shares: 7,843,040

Shares Outstanding: 10,829,760

2025-03-31

78.41%

Inst. Shares: 8,244,778

Shares Outstanding: 10,514,901

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	28,701,406	20,106,925	142.74%
2025-12-31	19,884,047	13,404,830	148.33%
2025-09-30	15,316,938	14,000,451	109.40%
2025-06-30	7,843,040	10,829,760	72.42%
2025-03-31	8,244,778	10,514,901	78.41%
2024-12-31	7,490,560	4,426,149	169.23%
2024-09-30	6,656,930	5,546,257	120.03%
2024-06-30	231,682	1,034,130	22.40%
2024-03-31	2,036,953	859,381	237.03%
2023-12-31	22,444	277,727	8.08%
2023-09-30	790,562	194,851	-
2023-06-30	2,371,286	58,217	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Avalo Therapeutics, Inc. (AVTX) — SEC Financial Statements & Analysis

Avalo Therapeutics, Inc. (AVTX) is a pharmaceutical preparations company, incorporated in DE. Avalo Therapeutics, Inc. trades on Nasdaq as: AVTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Avalo Therapeutics, Inc. reported a -86.62% year-over-year revenue growth, a Gross Profit Margin of 33.26% (TTM), a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of 13657.05x (TTM), a Price-to-Book (P/B) ratio of 1.80x (TTM), at a market cap of $805.77M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -86.62%
Gross Profit Margin TTM: 33.26%
Debt To Equity: 0.09x
P/S TTM: 13657.05x
P/B TTM: 1.80x
Market Cap: $805.77M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Avalo Therapeutics, Inc. in?

Avalo Therapeutics, Inc. (AVTX) operates in the Pharmaceutical Preparations industry.

What is AVTX's market cap?

Avalo Therapeutics, Inc. (AVTX) has a market capitalization of $805.77M as of 2026-06-30.

What exchange does AVTX trade on?

Avalo Therapeutics, Inc. (AVTX) trades on the Nasdaq.

Where is Avalo Therapeutics, Inc. incorporated?

Avalo Therapeutics, Inc. is incorporated in DE.